<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00068614</url>
  </required_header>
  <id_info>
    <org_study_id>PMXA1103</org_study_id>
    <secondary_id>CWRU-030339</secondary_id>
    <secondary_id>CDR0000327784</secondary_id>
    <secondary_id>PHARMEXA-PX104.1.6-101</secondary_id>
    <nct_id>NCT00068614</nct_id>
  </id_info>
  <brief_title>HER-2 Protein Vaccine in Treating Women With Breast Cancer</brief_title>
  <official_title>A Phase I Trial Evaluating The Safety Of Intramuscular Injections Of HER-2 Protein AUTOVAC (PX104.1.6) In Patients With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Case Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Case Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women&#xD;
      who have breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the safety of HER-2 protein AutoVac™ in women with breast cancer.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the ability of this drug to bypass the tolerance to the HER-2 self-protein by&#xD;
           raising HER-2 antibodies in these patients.&#xD;
&#xD;
        -  Determine the kinetics of the immune response to HER-2/neu in patients treated with this&#xD;
           drug.&#xD;
&#xD;
      OUTLINE: This is an open-label, multicenter study.&#xD;
&#xD;
      Patients receive HER-2 protein AutoVac™ intramuscularly at weeks 0, 2, 6, and 10 in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      Patients are followed for up to 6 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study within 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2003</start_date>
  <primary_completion_date type="Actual">October 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HER-2/neu peptide vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed adenocarcinoma of the breast, meeting criteria for 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Metastatic disease currently in complete or partial response or stable disease&#xD;
&#xD;
                    -  Have been receiving a stable endocrine therapy regimen (e.g., aromatase&#xD;
                       inhibitor, tamoxifen, fulvestrant, or gonadotropin-releasing hormone&#xD;
                       agonist) for at least 30 days OR status post oophorectomy&#xD;
&#xD;
               -  Completed a course of local and adjuvant systemic therapy for high-risk stage II&#xD;
                  or III disease (i.e., anticipated 5-year relative survival is no greater than&#xD;
                  50%) meeting any of the following staging criteria:&#xD;
&#xD;
                    -  Stage IIB with involvement of at least 4 nodes&#xD;
&#xD;
                    -  Stage IIIA (T3 disease with involvement of at least 4 nodes)&#xD;
&#xD;
                    -  Any stage IIIB or IIIC disease&#xD;
&#xD;
               -  Stage IV with no evidence of disease (e.g., prior resection of local chest wall&#xD;
                  recurrence with no evidence of disease elsewhere)&#xD;
&#xD;
          -  1+, 2+, or 3+ HER2/neu expression by immunohistochemistry&#xD;
&#xD;
          -  Treatment with trastuzumab (Herceptin®) not clinically indicated&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 6 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  ALT or AST no greater than 2.5 times upper limit of normal (ULN) (5 times ULN for&#xD;
             patients with liver metastases)&#xD;
&#xD;
          -  Bilirubin no greater than 2 mg/dL (unless due to Gilbert's disease)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No history of significant cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months&#xD;
&#xD;
          -  No poorly controlled cardiac arrhythmia&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  LVEF at least 50% by MUGA&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No other malignancy except basal cell skin cancer or adequately treated carcinoma in&#xD;
             situ of the cervix&#xD;
&#xD;
          -  No concurrent severe autoimmune disease&#xD;
&#xD;
          -  No other clinically significant or serious medical disease that would preclude study&#xD;
             participation or compromise patient safety or the results of this study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  More than 4 months since prior trastuzumab&#xD;
&#xD;
          -  No prior anticancer vaccine therapy&#xD;
&#xD;
          -  No concurrent trastuzumab&#xD;
&#xD;
          -  No concurrent immunomodulators (e.g., thalidomide or interferons/interleukins)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent low-dose methotrexate or cyclophosphamide&#xD;
&#xD;
          -  No concurrent cytotoxic chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent corticosteroids&#xD;
&#xD;
               -  Topical or inhaled steroids are allowed&#xD;
&#xD;
          -  No changes to current endocrine therapy regimen (e.g., discontinuation or addition of&#xD;
             an agent)&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 3 months since prior radiotherapy involving more than 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No prior bilateral breast procedures&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 4 weeks since prior immunosuppressive therapy&#xD;
&#xD;
          -  More than 30 days since prior investigational agents or clinical trial participation&#xD;
&#xD;
          -  No other concurrent experimental or investigational agents&#xD;
&#xD;
          -  No concurrent cyclosporine&#xD;
&#xD;
          -  No concurrent immunosuppressive agents&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth A. Overmoyer, MD, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>Case Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ireland Cancer Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <study_first_submitted>September 10, 2003</study_first_submitted>
  <study_first_submitted_qc>September 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 11, 2003</study_first_posted>
  <last_update_submitted>February 4, 2014</last_update_submitted>
  <last_update_submitted_qc>February 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IV breast cancer</keyword>
  <keyword>stage II breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

